Literature DB >> 21504401

Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: an update.

Jean-Michel Garcia1, Jimmy C C Lai.   

Abstract

Pseudotyped viral particles are being used as safe surrogates to mimic the structure and surface of many viruses, including highly pathogenic viruses such as avian influenza H5N1, to investigate biological functions mediated by the envelope proteins derived from these viruses. The first part of this article evaluates and discusses the differences in the production and characterization of influenza pseudoparticles. The second part focuses on the applications that such a flexible tool can provide in modern influenza research, in particular in the fields of drug discovery, molecular biology and diagnosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21504401     DOI: 10.1586/eri.11.25

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  13 in total

1.  Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.

Authors:  Yi Lu; Taijiao Jiang
Journal:  Protein Cell       Date:  2013-04-15       Impact factor: 14.870

Review 2.  Pseudotype-based neutralization assays for influenza: a systematic analysis.

Authors:  George William Carnell; Francesca Ferrara; Keith Grehan; Craig Peter Thompson; Nigel James Temperton
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

3.  Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions.

Authors:  Aleksandar Antanasijevic; Carolyn Kingsley; Arnab Basu; Terry L Bowlin; Lijun Rong; Michael Caffrey
Journal:  J Biomol NMR       Date:  2016-02-26       Impact factor: 2.835

4.  A single residue substitution in the receptor-binding domain of H5N1 hemagglutinin is critical for packaging into pseudotyped lentiviral particles.

Authors:  Dong-Jiang Tang; Yuen-Man Lam; Yu-Lam Siu; Chi-Hong Lam; Shui-Ling Chu; J S Malik Peiris; Philippe Buchy; Béatrice Nal; Roberto Bruzzone
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

5.  The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes.

Authors:  Francesca Ferrara; Eleonora Molesti; Eva Böttcher-Friebertshäuser; Giovanni Cattoli; Davide Corti; Simon D Scott; Nigel J Temperton
Journal:  J Mol Genet Med       Date:  2013-02-20

6.  The use of equine influenza pseudotypes for serological screening.

Authors:  Simon Scott; Eleonora Molesti; Nigel Temperton; Francesca Ferrara; Eva Böttcher-Friebertshäuser; Janet Daly
Journal:  J Mol Genet Med       Date:  2012-12-31

7.  An Innovative Pseudotypes-Based Enzyme-Linked Lectin Assay for the Measurement of Functional Anti-Neuraminidase Antibodies.

Authors:  Marua Prevato; Roberta Cozzi; Alfredo Pezzicoli; Anna Rita Taddei; Ilaria Ferlenghi; Avishek Nandi; Emanuele Montomoli; Ethan C Settembre; Sylvie Bertholet; Alessandra Bonci; Francois Legay
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

Review 8.  Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.

Authors:  Claudia Maria Trombetta; Daniele Perini; Stuart Mather; Nigel Temperton; Emanuele Montomoli
Journal:  Vaccines (Basel)       Date:  2014-10-13

9.  Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody.

Authors:  Oi-Wing Ng; Choong-Tat Keng; Cynthia Sau-Wai Leung; J S Malik Peiris; Leo Lit Man Poon; Yee-Joo Tan
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

10.  Cleavage of hemagglutinin-bearing lentiviral pseudotypes and their use in the study of influenza virus persistence.

Authors:  Olivier Sawoo; Amélie Dublineau; Christophe Batéjat; Paul Zhou; Jean-Claude Manuguerra; India Leclercq
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.